Daiichi Sankyo starts phase III of Enbrel biosimilar in Japan

Enbrel (Etanercept), a fully human soluble TNFα receptor preparation, is a therapeutic for rheumatoid arthritis.

Daiichi Sankyo news release, August 18, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny